You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞太藥業(002370.SZ)收到注射用頭孢美唑鈉一致性評價受理通知書
格隆匯 04-17 21:00

格隆匯4月17日丨亞太藥業(002370.SZ)公佈,公司於近日收到國家藥品監督管理局下發的關於注射用頭孢美唑鈉一致性評價的受理通知書。

頭孢美唑鈉為第二代頭孢菌素,對陰性桿菌產生的廣譜β-內酰胺酶有較好的穩定性。該品適用於治療由對頭孢美唑鈉敏感的金黃色葡萄球菌、大腸埃希菌、肺炎桿菌、變形桿菌屬、摩氏摩根菌、普羅威登斯菌屬、消化鏈球菌屬、擬桿菌屬、普雷沃菌屬(雙路普雷沃菌除外)所引起的下述感染:敗血症;急性支氣管炎、肺炎、肺膿腫、膿胸、慢性呼吸道疾病繼發感染;膀胱炎、腎盂腎炎;腹膜炎;膽囊炎、膽管炎;前庭大腺炎、子宮內感染、子宮附件炎、子宮旁組織炎;頜骨周圍蜂窩織炎、頜炎。

注射用頭孢美唑鈉被國家藥品監督管理局藥品審評中心受理,標誌着該品種一致性評價工作進入了審評階段,公司將積極推進後續相關工作,如順利通過一致性評價將增加其市場競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account